Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity
about
Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseasesThe role of the LRRK2 gene in ParkinsonismPhosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPasesBehavioral Phenotyping and Pathological Indicators of Parkinson's Disease in C. elegans Models.Glutaredoxin deficiency exacerbates neurodegeneration in C. elegans models of Parkinson's disease.The roles of redox enzymes in Parkinson's disease: Focus on glutaredoxin.Oxidative stress mechanisms underlying Parkinson's disease-associated neurodegeneration in C. elegans.Genetic insights into sporadic Parkinson's disease pathogenesis.Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic NeurotransmissionTTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.LRRK2: cause, risk, and mechanism.Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation.LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesisGenetic, structural, and molecular insights into the function of ras of complex proteins domains.Use of Caenorhabditis elegans as a model to study Alzheimer's disease and other neurodegenerative diseases.Combating neurodegenerative disease with chemical probes and model systems.LRRK2 Pathways Leading to Neurodegeneration.Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation.In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2.Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradationPhosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1.Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.Trace analysis of methylated and hydroxymethylated cytosines in DNA by isotope-dilution LC-MS/MS: first evidence of DNA methylation in Caenorhabditis elegans.The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm.Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.Mechanisms of Mutant LRRK2 Neurodegeneration.LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.Modeling Parkinson's Disease in C. elegans.Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson's disease.LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation
P2860
Q26776093-DB9094A8-E6D1-49CD-975E-5BD5A5159F28Q27023749-F0560BD5-8F2B-478D-9F85-0B00DAD28B40Q28119192-D6C8A74E-E6E5-4D78-BF6E-EFE925E9CB7BQ33790301-9DB7AEA9-5EC2-41B6-A9BC-58562D49DCFDQ35063145-0EFC74F9-A585-4AD1-B015-3064CBEF5441Q35761021-70F3CB04-DE61-4474-A747-330C3F5DCA83Q37375576-637AD43C-703B-43D2-A85A-C7F6D2EB5F9EQ37583402-7ACBDD6D-D885-48D9-B57D-3D40813D6E4CQ37595917-793D1D58-6526-49D8-85A2-D19AD2462506Q37623535-1A664BF3-DB45-4078-BACD-C2CD3851F6D6Q37635000-2BA3F886-6BA7-4AF1-AC3A-5AB84800A123Q38213378-A8B422C3-D799-4BE3-9A2D-2CF225984745Q38218398-B309EA92-BAA3-4611-B3A2-C96538569FA2Q38225040-1D0BE3A7-B96D-4FD0-A14A-3B52FF3C85ADQ38253642-20B4A53A-DAA5-4FE3-BC66-8DC6A4D76DBEQ38261089-77ADB368-9E6F-4C16-887B-8BE6E590EE1EQ38501861-9B2A8ECB-16F4-44DD-8F21-631EBB12B151Q39137358-A3148024-84ED-4CE5-98B6-FC2683015240Q40188432-F0CC378B-9C57-415E-BB24-43EAD5D98A16Q41020334-0C104C99-E725-4C93-BD59-5F7F76F6B2AAQ41163700-1809E279-5E43-4DEE-B8FD-F34750239AC6Q42263195-E0B538F3-B1C1-4A86-A8BE-9B2E7B4836A5Q42372493-28D90758-9068-45EE-881F-5733D3698421Q43985517-AC3AC591-975F-4A4A-8463-7E5ED93DDB4BQ46428440-5B3C9113-C1C1-4E58-82A4-D18C5215409BQ46520584-1C800755-8E2E-472B-B4D2-F53EE508CA46Q48239635-BEF3F73A-C4C1-4DEB-861F-DDBFD74B0052Q48560989-B7375C22-2F5D-4BDF-AF35-4E4843DD09B1Q51767278-DF94403C-AEB1-4B90-97B0-35346F6B146BQ54972398-BE992171-DA7A-4F47-92BF-6C96FFEEC170Q58701452-47FCF340-45EC-4CE9-9C7A-4B9889C2EE92
P2860
Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Kinase inhibitors arrest neuro ...... egans models of LRRK2 toxicity
@ast
Kinase inhibitors arrest neuro ...... egans models of LRRK2 toxicity
@en
type
label
Kinase inhibitors arrest neuro ...... egans models of LRRK2 toxicity
@ast
Kinase inhibitors arrest neuro ...... egans models of LRRK2 toxicity
@en
prefLabel
Kinase inhibitors arrest neuro ...... egans models of LRRK2 toxicity
@ast
Kinase inhibitors arrest neuro ...... egans models of LRRK2 toxicity
@en
P2093
P2860
P50
P921
P356
P1476
Kinase inhibitors arrest neuro ...... egans models of LRRK2 toxicity
@en
P2093
Amy L Wilson-Delfosse
Hanno Roder
John J Mieyal
William M Johnson
P2860
P304
P356
10.1093/HMG/DDS431
P577
2012-10-12T00:00:00Z